Zirconium Zr 89-Df-Crefmirlimab

Phase 1Monoclonal antibody

Zirconium Zr 89-Df-Crefmirlimab is one of 2 small molecule programs targeting Stereotactic Body Radiation Therapy. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Stereotactic Body Radiation TherapyRecruiting

Stereotactic Body Radiation TherapyPhase 1

Recruiting

Competition

Competitive Landscape

1 competitor in Stereotactic Body Radiation Therapy

#DrugCompanyPhaseTrials

Stereotactic Body Radiation Therapy

RRoswell Park Cancer Institute

Phase 2

1 2

Zirconium Zr 89-Df-Crefmirlimab

CCity of Hope Medical Center

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Recruiting

Stereotactic Body Radiation Therapy

NCT05371132

Clinical

Trials by Indication[1]

Stereotactic Body Radiation Therapy1 trial

Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)

Recruiting·—·Phase 1·NCT05371132·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Zirconium Zr 89-Df-Crefmirlimab. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Zirconium Zr 89-Df-Crefmirlimab compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Zirconium Zr 89-Df-Crefmirlimab. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — City of Hope Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Monoclonal antibody[2]
Highest Phase: Phase 1[1]
Company: CCity of Hope Medical Center

Zirconium Zr 89-Df-Crefmirlimab

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Stereotactic Body Radiation Therapy1 trial

References

Drug Info

Quick Facts

Related News